Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial

CGJI. van Straten, C. Caris, MO. Grimm, M. Colombel, T. Muilwijk, L. Martínez-Piñeiro, MM. Babjuk, LN. Türkeri, J. Palou, A. Patel, AS. Bjartell, WPJ. Witjes, AG. van der Heijden, LALM. Kiemeney

. 2023 ; 56 (-) : 15-24. [pub] 20230912

Status not-indexed Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23022797

BACKGROUND: Adverse events induced by intravesical bacillus Calmette-Guérin (BCG) to treat high-grade non-muscle-invasive bladder cancer (NMIBC) often lead to treatment discontinuation. The EAU-RF NIMBUS trial found a reduced number of standard-dose BCG instillations to be inferior with the standard regimen. Nonetheless, it remains important to evaluate whether patients in the reduced BCG treatment arm had better quality of life (QoL) due to a possible reduction in toxicity or burden. OBJECTIVE: To evaluate whether patients in the EAU-RF NIMBUS trial experienced better QoL after a reduced BCG instillation frequency. DESIGN SETTING AND PARTICIPANTS: A total of 359 patients from 51 European sites were randomized to one of two treatment arms between December 2013 and July 2019. The standard frequency arm (n = 182) was 6 weeks of BCG induction followed by 3 weeks of maintenance at months 3, 6, and 12. The reduced frequency arm (n = 177) was BCG induction at weeks 1, 2, and 6, followed by maintenance instillations at weeks 1 and 3 of months 3, 6, and 12. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Analyses were performed using an intention-to-treat analysis and a per-protocol analysis. QoL was measured using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 version 3.0 (QLQ-C30 v.03) prior to the first and last instillations of each BCG cycle. Group differences were determined using linear regression corrected for QoL at baseline. Differences in QoL over time were tested for significance using a linear mixed model. Side effects were recorded by the treating physician using a standardized form. Chi-square tests were used to compare the side-effect frequency between the arms. RESULTS AND LIMITATIONS: There were no significant differences in the means of each QoL scale between the two arms. There were also no significant changes over time in all QoL domains for both arms. However, differences in the incidence of general malaise at T1 (before the last induction instillation), frequency, urgency, and dysuria at T7 (before the last maintenance instillation) were detected in favor of the reduced frequency arm. CONCLUSIONS: Reducing the BCG instillation frequency does not improve the QoL in NMIBC patients despite lower storage symptoms. PATIENT SUMMARY: In this study, we evaluated whether a reduction in the number of received bacillus Calmette-Guérin instillations led to better quality of life in patients with high-grade non-muscle-invasive bladder cancer. We found no difference in the quality of life between the standard and the reduced bacillus Calmette-Guérin instillation frequency. We conclude that reducing the number of instillations does not lead to better quality of life in patients with high-grade non-muscle-invasive bladder cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23022797
003      
CZ-PrNML
005      
20240116163135.0
007      
ta
008      
240105s2023 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euros.2023.08.004 $2 doi
035    __
$a (PubMed)37822514
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a van Straten, Christine G J I $u Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
245    10
$a Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial / $c CGJI. van Straten, C. Caris, MO. Grimm, M. Colombel, T. Muilwijk, L. Martínez-Piñeiro, MM. Babjuk, LN. Türkeri, J. Palou, A. Patel, AS. Bjartell, WPJ. Witjes, AG. van der Heijden, LALM. Kiemeney
520    9_
$a BACKGROUND: Adverse events induced by intravesical bacillus Calmette-Guérin (BCG) to treat high-grade non-muscle-invasive bladder cancer (NMIBC) often lead to treatment discontinuation. The EAU-RF NIMBUS trial found a reduced number of standard-dose BCG instillations to be inferior with the standard regimen. Nonetheless, it remains important to evaluate whether patients in the reduced BCG treatment arm had better quality of life (QoL) due to a possible reduction in toxicity or burden. OBJECTIVE: To evaluate whether patients in the EAU-RF NIMBUS trial experienced better QoL after a reduced BCG instillation frequency. DESIGN SETTING AND PARTICIPANTS: A total of 359 patients from 51 European sites were randomized to one of two treatment arms between December 2013 and July 2019. The standard frequency arm (n = 182) was 6 weeks of BCG induction followed by 3 weeks of maintenance at months 3, 6, and 12. The reduced frequency arm (n = 177) was BCG induction at weeks 1, 2, and 6, followed by maintenance instillations at weeks 1 and 3 of months 3, 6, and 12. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Analyses were performed using an intention-to-treat analysis and a per-protocol analysis. QoL was measured using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 version 3.0 (QLQ-C30 v.03) prior to the first and last instillations of each BCG cycle. Group differences were determined using linear regression corrected for QoL at baseline. Differences in QoL over time were tested for significance using a linear mixed model. Side effects were recorded by the treating physician using a standardized form. Chi-square tests were used to compare the side-effect frequency between the arms. RESULTS AND LIMITATIONS: There were no significant differences in the means of each QoL scale between the two arms. There were also no significant changes over time in all QoL domains for both arms. However, differences in the incidence of general malaise at T1 (before the last induction instillation), frequency, urgency, and dysuria at T7 (before the last maintenance instillation) were detected in favor of the reduced frequency arm. CONCLUSIONS: Reducing the BCG instillation frequency does not improve the QoL in NMIBC patients despite lower storage symptoms. PATIENT SUMMARY: In this study, we evaluated whether a reduction in the number of received bacillus Calmette-Guérin instillations led to better quality of life in patients with high-grade non-muscle-invasive bladder cancer. We found no difference in the quality of life between the standard and the reduced bacillus Calmette-Guérin instillation frequency. We conclude that reducing the number of instillations does not lead to better quality of life in patients with high-grade non-muscle-invasive bladder cancer.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Caris, Christien $u EAU Research Foundation, Arnhem, The Netherlands
700    1_
$a Grimm, Marc-Oliver $u Department of Urology, Jena University Hospital, Jena, Germany
700    1_
$a Colombel, Marc $u Department of Urology, Hospital Edouard Herriot, Lyon, France
700    1_
$a Muilwijk, Tim $u Department of Urology, University Hospitals Leuven, Leuven, Belgium
700    1_
$a Martínez-Piñeiro, Luis $u Department of Urology, Hospital Universitario La Paz, Madrid, Spain
700    1_
$a Babjuk, Marko M $u Department of Urology, Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Türkeri, Levent N $u Department of Urology, Acıbadem University, Istanbul, Turkey
700    1_
$a Palou, Joan $u Urology Department, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain
700    1_
$a Patel, Anup $u London, UK
700    1_
$a Bjartell, Anders S $u Skåne University Hospital, Lund University, Lund, Sweden
700    1_
$a Witjes, Wim P J $u EAU Research Foundation, Arnhem, The Netherlands
700    1_
$a van der Heijden, Antoine G $u Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
700    1_
$a Kiemeney, Lambertus A L M $u Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
773    0_
$w MED00207999 $t European urology open science $x 2666-1683 $g Roč. 56, č. - (2023), s. 15-24
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37822514 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240105 $b ABA008
991    __
$a 20240116163132 $b ABA008
999    __
$a ok $b bmc $g 2036397 $s 1209242
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 56 $c - $d 15-24 $e 20230912 $i 2666-1683 $m European urology open science $n Eur Urol Open Sci $x MED00207999
LZP    __
$a Pubmed-20240105

Find record

Citation metrics

Archiving options